Summary:
To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD). Subjects will be considered to have treatment resistant MDD if they have had a historical inadequate response to 1 or 2 antidepressant treatments. Study may last up to 12 weeks.
Qualified Participants Must:
• Be between 18 and 65 years of age (Adult)
•
Have a history of inadequate response to 1 or 2 adequate antidepressant treatments
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.